Claims
- 1. A composition comprising:
a therapeutic agent comprising hydrothermally synthesized 90-yttrium phosphate particles; and a therapeutic agent carrier comprising fibrin, wherein the therapeutic agent is mixed with the therapeutic agent carrier.
- 2. The composition of claim 1, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 3 μm.
- 3. The composition of claim 1, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 0.8 μm.
- 4. The composition of claim 1, wherein the 90-yttrium phosphate particles have an average diameter of from about 0.3 to about 0.8 μm.
- 5. The composition of claim 1, wherein a substantial amount of the 90-yttrium phosphate particles are substantially spherical.
- 6. The composition of claim 2, wherein the therapeutic agent comprises a colloid, wherein the 90-yttrium phosphate particles comprise a disperse phase of the colloid.
- 7. The composition of claim 6, wherein the therapeutic agent carrier further comprises a stimulus sensitive gelling polymer.
- 8. The composition of claim 7, wherein the stimulus sensitive gelling polymer is a thermogelling biodegradable polymer comprising a polyethylene glycol block and a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure satisfying the formula An(B), wherein n is equal to or greater than 2, A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different than B.
- 9. The composition of claim 7, wherein the stimulus sensitive gelling polymer is a thermogelling biodegradable polymer carrier comprising a biocompatible polymer block and a biodegradable polypeptide block, wherein the biocompatible polymer and the polypeptide blocks are linked to form a polymer of a general structure satisfying the formula CnDm, wherein n is equal to or greater than 1, m is equal to or greater than 1, C is a biodegradable polypeptide block, and D is a biocompatible soluble polymer having a chain length such that if D is not biodegradable, D may be eliminated through a glomeruli filtration system.
- 10. A composition comprising,
a therapeutic agent carrier comprising a thermogelling, biodegradable, polymer comprising a polyethylene glycol block and a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure satisfying the formula An(B), wherein n is equal to or greater than 2, A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different than B; and a therapeutic agent comprising hydrothermally synthesized 90-yttrium phosphate particles, wherein the therapeutic agent is mixed with the therapeutic agent carrier.
- 11. The composition of claim 10, wherein n is between 3 and 10.
- 12. The composition of claim 11, wherein the polyethylene glycol has an average molecular weight of between 200 and 20,000.
- 13. The composition of claim 10, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 3 μm.
- 14. The composition of claim 13, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 0.8 μm.
- 15. The composition of claim 10, wherein the 90-yttrium phosphate particles have an average diameter of from about 0.3 to about 0.8 μm.
- 16. The composition of claim 14, wherein a substantial amount of the 90-yttrium phosphate particles are substantially spherical.
- 17. The composition of claim 14, wherein about 40% of the 90-yttrium phosphate particles are substantially spherical.
- 18. The composition of claim 13, wherein the therapeutic agent comprises a colloid, wherein the 90-yttrium phosphate particles comprise a disperse phase of the colloid.
- 19. A composition comprising:
a therapeutic agent carrier comprising a thermogelling, biodegradable, polymer carrier comprising a biocompatible polymer block and a biodegradable polypeptide block, wherein the biocompatible polymer and the polypeptide blocks are linked to form a polymer of a general structure satisfying the formula CnDm, wherein n is equal to or greater than 1, m is equal to or greater than 1, C is a biodegradable polypeptide block, D is a biocompatible soluble polymer having a chain length such that if D is not biodegradable, D may be eliminated through a glomeruli filtration system; and a therapeutic agent comprising hydrothermally synthesized 90-yttrium phosphate particles, wherein the therapeutic agent is mixed with the therapeutic agent carrier.
- 20. The composition of claim 19, wherein D comprises a polyethylene glycol block.
- 21. The composition of claim 20, wherein the polypeptide block has an average molecular weight of from about 300 to about 30,000.
- 22. The composition of claim 19, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 3 μm.
- 23. The composition of claim 22, wherein the 90-yttrium phosphate particles have a mean diameter of from about 0.3 to about 0.8 μm.
- 24. The composition of claim 22, wherein a substantial amount of the 90-yttrium phosphate particles are substantially spherical.
- 25. The composition of claim 22, wherein the therapeutic agent comprises a colloid, wherein the 90-yttrium phosphate particles comprise a disperse phase of the colloid.
- 26. A method for making a therapeutic agent carrier comprising:
forming a therapeutic agent carrier comprising a stimulus-sensitive gelling polymer, fibrin, or combinations thereof; and mixing a hydrothermally synthesized radioactive therapeutic agent with the therapeutic agent carrier.
- 27. The method of claim 26, wherein hydrothermally synthesizing the radioactive therapeutic agent comprises hydrothermally synthesizing a 90-yttrium phosphate colloid by reacting a yttrium source, EDTA, and a phosphate source.
- 28. The method of claim 27, wherein the 90-yttrium source, EDTA, and phosphate source are reacted in an acidic environment.
- 29. The method of claim 28, wherein the 90-yttrium source, EDTA, and phosphate source are reacted at a pH of from about 6 to about 6.5.
- 30. The method of claim 28, wherein the 90-yttrium source, EDTA, and phosphate source are reacted at a temperature of at least about 150° C.
- 31. The method of claim 30, wherein the 90-yttrium source, EDTA, and phosphate source are reacted for at least about 20 hours.
- 32. The method of claim 27, wherein the yttrium source comprises 90YCl3.
- 33. The method of claim 32, wherein the phosphate source comprises NaH2PO4.
- 34. The method of claim 27, wherein the 90-yttrium source, EDTA, and phosphate source are combined in a yttrium source:EDTA:phosphate source ratio of about 1:1:6.
- 35. A method of treating cancer in a subject comprising:
resecting a tumor from a subject, wherein resection of the tumor creates a tumor removal site; and applying a therapeutic agent carrier composition to intact tissue at the tumor resection site in an amount effective to destroy vestigial cancerous cells, wherein the therapeutic agent carrier composition comprises a hydrothermally synthesized 90-yttrium phosphate colloid and a therapeutic agent carrier, wherein the therapeutic agent carrier is a) fibrin, b) a thermogelling, biodegradable polymer carrier comprising a polyethylene glycol block and a biodegradable polyester block, wherein said blocks are linked to form a polymer of a general structure satisfying the formula An(B), wherein n is equal to or greater than 2, and A is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, B is selected from the group consisting of a polyethylene glycol block and a biodegradable polyester block, and A is different than B, c) a thermogelling, biodegradable polymer carrier comprising a biocompatible polymer block and a biodegradable polypeptide block, wherein the biocompatible polymer and the polypeptide blocks are linked to form a polymer of a general structure satisfying the formula CnDm, wherein n is equal to or greater than 1, m is equal to or greater than 1, C is a biodegradable polypeptide block, D is a biocompatible soluble polymer having a chain length such that if D is not biodegradable, D may be eliminated through a glomeruli filtration system, or d) combinations thereof.
CROSS REFERENCE TO RELATED APPLICATION
[0001] This disclosure is a Continuation-In-Part of application Ser. No. 09/994,509, filed Nov. 26, 2001, which is a Continuation-In-Part Application of application Ser. No. 09/853,507, filed May 9, 2001, which is a Continuation of application Ser. No. 09/058,712, filed Apr. 10, 1998, now U.S. Pat. No. 6,296,831, and is a Continuation-in-Part of application Ser. No. 10/124,614, filed Apr. 16, 2002, which is a Continuation-in-Part of application Ser. No. 09/833,460, filed Apr. 11, 2001, which application claims the benefit under 35 U.S.C. §119(e) of provisional Patent Application No. 60/236,926, filed Sep. 28, 2000, which are all incorporated by reference herein.
Government Interests
[0002] The disclosed compositions were made with Government support under Contract DE-AC06 76RLO 1830 awarded by the U.S. Department of Energy. The Government has certain rights in this patent.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60236926 |
Sep 2000 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09058712 |
Apr 1998 |
US |
Child |
09853507 |
May 2001 |
US |
Continuation in Parts (4)
|
Number |
Date |
Country |
Parent |
09994509 |
Nov 2001 |
US |
Child |
10784147 |
Feb 2004 |
US |
Parent |
09853507 |
May 2001 |
US |
Child |
09994509 |
Nov 2001 |
US |
Parent |
10124614 |
Apr 2002 |
US |
Child |
10784147 |
Feb 2004 |
US |
Parent |
09833460 |
Apr 2001 |
US |
Child |
10124614 |
Apr 2002 |
US |